News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
44,097 Results
Type
Article (3517)
Company Profile (26)
Press Release (40554)
Section
Business (13938)
Career Advice (55)
Deals (1758)
Drug Delivery (7)
Drug Development (3687)
Employer Resources (3)
FDA (565)
Job Trends (1241)
News (19585)
Policy (1316)
Tag
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Pharm Country Digital (1)
Academia (425)
Allergies (3)
Alliances (5536)
ALS (6)
Alzheimer's disease (55)
Antibody-drug conjugate (ADC) (2)
Approvals (568)
Artificial intelligence (30)
Autoimmune disease (1)
Automation (6)
Bankruptcy (15)
Best Places to Work (1099)
BIOSECURE Act (12)
Biosimilars (1)
Biotechnology (24)
Bladder cancer (6)
Brain cancer (3)
Breast cancer (44)
Cancer (244)
Cardiovascular disease (7)
Career advice (55)
Career pathing (1)
CAR-T (8)
Cell therapy (43)
Cervical cancer (1)
Clinical research (2572)
Collaboration (109)
Compensation (20)
Complete response letters (1)
COVID-19 (197)
CRISPR (17)
C-suite (12)
Cystic fibrosis (7)
Data (168)
Diabetes (13)
Diagnostics (1394)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (10)
Drug pricing (1)
Duchenne muscular dystrophy (5)
Earnings (3315)
Editorial (1)
Employer branding (1)
Employer resources (3)
Events (6247)
Executive appointments (62)
FDA (616)
Featured Employer (6)
Funding (46)
Gene editing (47)
Generative AI (2)
Gene therapy (43)
GLP-1 (33)
Government (289)
Guidances (5)
Healthcare (1215)
Huntington's disease (1)
Immunology and inflammation (2)
Infectious disease (207)
Inflammatory bowel disease (10)
Influenza (5)
Intellectual property (8)
Interviews (4)
IPO (766)
Job creations (177)
Job search strategy (52)
Layoffs (17)
Legal (201)
Liver cancer (7)
Lung cancer (42)
Lymphoma (9)
Management (1)
Manufacturing (25)
MASH (1)
Medical device (334)
Medtech (335)
Mergers & acquisitions (1017)
Metabolic disorders (20)
NASH (1)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (81)
NextGen: Class of 2025 (375)
Non-profit (291)
Northern California (233)
Now hiring (2)
Obesity (5)
Opinion (26)
Ovarian cancer (1)
Pain (3)
Pancreatic cancer (10)
Parkinson's disease (8)
Partnered (1)
Patents (10)
Patient recruitment (2)
Peanut (1)
People (4387)
Pharmaceutical (2)
Phase I (1150)
Phase II (1218)
Phase III (792)
Pipeline (57)
Policy (14)
Postmarket research (37)
Preclinical (630)
Press Release (22)
Prostate cancer (8)
Radiopharmaceuticals (3)
Rare diseases (36)
Real estate (350)
Regulatory (937)
Reports (3)
Research institute (509)
Resumes & cover letters (2)
RSV (1)
Schizophrenia (1)
Series A (11)
Series B (5)
Sickle cell disease (14)
Southern California (218)
Spinal muscular atrophy (2)
Sponsored (2)
Startups (357)
Supply chain (5)
United States (1630)
Vaccines (21)
Venture capitalists (2)
Weight loss (4)
Date
Last 7 days (34)
Last 30 days (152)
Last 365 days (2622)
2025 (534)
2024 (2760)
2023 (3221)
2022 (4332)
2021 (4506)
2020 (3835)
2019 (2910)
2018 (2174)
2017 (2496)
2016 (2397)
2015 (2466)
2014 (1588)
2013 (1371)
2012 (1401)
2011 (1392)
2010 (1228)
Location
Africa (57)
Alabama (8)
Alaska (1)
Arizona (22)
Asia (2237)
Australia (353)
California (555)
Canada (74)
China (42)
Colorado (11)
Connecticut (30)
Delaware (4)
Europe (5666)
Florida (54)
Georgia (4)
Idaho (1)
Illinois (20)
India (3)
Indiana (9)
Iowa (3)
Japan (16)
Kansas (2)
Kentucky (1)
Louisiana (1)
Maine (3)
Maryland (56)
Massachusetts (326)
Michigan (13)
Minnesota (18)
Missouri (6)
Montana (2)
Nebraska (5)
Nevada (5)
New Hampshire (2)
New Jersey (86)
New Mexico (11)
New York (71)
North Carolina (118)
North Dakota (6)
Northern California (233)
Ohio (17)
Oregon (1)
Pennsylvania (46)
Rhode Island (3)
South America (59)
South Carolina (2)
Southern California (218)
Tennessee (3)
Texas (86)
Utah (22)
Virginia (5)
Washington D.C. (4)
Washington State (34)
Wisconsin (8)
44,097 Results for "oryzon genomics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ORYZON to Provide Corporate Progress Updates at Several Events in March-April 2025
March 17, 2025
·
8 min read
Genetown
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
Oryzon Genomics, S.A. announced the voting results from its Annual General Meeting of Shareholders held in Madrid.
June 28, 2024
·
4 min read
Press Releases
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
February 28, 2025
·
19 min read
Genetown
ORYZON to Provide Corporate Progress Updates at Several Events in June
Oryzon Genomics, S.A announced today that its management will give an update on corporate progress at several international events in June.
May 30, 2024
·
8 min read
Press Releases
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting
January 27, 2025
·
9 min read
Press Releases
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
March 3, 2025
·
9 min read
Policy
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
Oryzon Genomics, S.A. announced that the European Patent Office has issued an “intention to grant” communication for Oryzon’s European patent application EP18748921.6 entitled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.
April 22, 2024
·
7 min read
Press Releases
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
February 17, 2025
·
8 min read
Press Releases
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
January 21, 2025
·
4 min read
Press Releases
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
March 5, 2025
·
9 min read
1 of 4,410
Next
